ClinicalTrials.gg

Program

selexipag

Also written as “Selexipag”, “selexipag (Uptravi)” and “Selexipag Film Coated Tablets (T1)”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Hypertension · Scleroderma, Systemic · Sarcoidosis, led by 2 companies.

Furthest: phase 4, since Mar 6, 201723 company-led studies, 3 open or runningNext primary completion: Jan 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson213 open or runningphase 4since Mar 6, 2017Apr 2, 2010Jan 31, 2027phase 3 · NCT05179876
Humanis Saglık Anonim Sirketi20 open or runningphase 1since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Apr 2, 2010.

  1. Jun 2, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02791815 · 20 enrolled · France
  2. Aug 18, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02882425 · 19 enrolled
  3. Mar 6, 2017Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03078907 · 108 enrolled · United States, Austria, France and more
  4. Jun 9, 2017Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03187678 · 20 enrolled · United States, Germany
  5. Apr 3, 2018Phase 2 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03492177 · 63 enrolled · United States, Belarus, Belgium and more
  6. Apr 6, 2018Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT03496506 · 22 enrolled · Belgium
  7. Sep 27, 2018Phase 3 study in Chronic Thromboembolic Pulmonary HypertensionJohnson & Johnson · NCT03689244 · 128 enrolled · United States, Argentina, Australia and more
  8. May 7, 2019Phase 2 study in SarcoidosisJohnson & Johnson · NCT03942211 · 10 enrolled · United States, Belgium, Brazil and more
  9. Nov 8, 2019Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT04175600 · 138 enrolled · United States, Australia, Belarus and more
  10. Jun 15, 2020Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT04435782 · 9 enrolled · United States, Argentina, Brazil and more
  11. Sep 22, 2020Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT04565990 · 43 enrolled · Belarus, India, Korea, Republic of and more
  12. Dec 17, 2021Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT05179876 · 280 planned · Belarus, Belgium, Bulgaria and more
  13. Apr 10, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06932198 · 14 enrolled · Jordan
  14. Jul 3, 2026Phase 1 study in HypertensionHumanis Saglık Anonim Sirketi · NCT07694128 · 30 enrolled · India

Ahead

  1. Jan 31, 2027Primary completion: phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT05179876

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
treprostinilruleUnited Therapeuticsphase 473

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07694128Hypertension · India1CompletedHumanis Saglık Anonim SirketiJun 16, 202630
NCT06932198Pulmonary Arterial Hypertension · Jordan1CompletedHumanis Saglık Anonim SirketiMar 3, 202514
NCT05179876Hypertension, Pulmonary · Belarus, Belgium, Bulgaria and more3RecruitingJohnson & JohnsonJan 31, 2027280
NCT04565990Hypertension, Pulmonary · Belarus, India, Korea, Republic of and more3CompletedJohnson & JohnsonNov 10, 202343
NCT04435782Pulmonary Arterial Hypertension · United States, Argentina, Brazil and more4TerminatedJohnson & JohnsonJul 28, 20239
NCT04175600Hypertension, Pulmonary · United States, Australia, Belarus and more3Active, not recruitingJohnson & JohnsonOct 11, 2024138
NCT03942211Sarcoidosis · United States, Belgium, Brazil and more2TerminatedJohnson & JohnsonApr 19, 202310
NCT03689244Chronic Thromboembolic Pulmonary Hypertension · United States, Argentina, Australia and more3TerminatedJohnson & JohnsonJun 7, 2022128
NCT03496506Healthy Subjects · Belgium1CompletedJohnson & JohnsonMay 10, 201822
NCT03492177Pulmonary Arterial Hypertension · United States, Belarus, Belgium and more2Active, not recruitingJohnson & JohnsonMar 28, 202263
NCT03187678Pulmonary Arterial Hypertension · United States, Germany3CompletedJohnson & JohnsonMay 29, 201820
NCT03078907Pulmonary Arterial Hypertension · United States, Austria, France and more4CompletedJohnson & JohnsonFeb 10, 2020108
NCT02882425Healthy Subjects1CompletedJohnson & JohnsonApr 201519
NCT02791815Healthy Subjects · France1CompletedJohnson & JohnsonSep 201620
NCT02770222Healthy Subjects1CompletedJohnson & JohnsonJul 201640
NCT02745860Healthy Subjects1CompletedJohnson & JohnsonJun 201620
NCT02558231Pulmonary Arterial Hypertension · United States, Australia, Austria and more3CompletedJohnson & JohnsonAug 29, 2019247
NCT02471183Pulmonary Arterial Hypertension · United States3CompletedJohnson & JohnsonDec 5, 201634
NCT02260557Scleroderma, Systemic · France, Germany, United Kingdom2CompletedJohnson & JohnsonApr 30, 201574
NCT02206295Bioequivalence1CompletedJohnson & JohnsonDec 201280
NCT02206204Cardiodynamics · United States1CompletedJohnson & JohnsonNov 2012159
NCT01112306Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedJohnson & JohnsonAug 26, 2021709
NCT01106014Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedJohnson & JohnsonApr 1, 20141,156

How it is read

Names in the registry

  • “Selexipag”, 13 entries
  • “selexipag”, 2 entries
  • “selexipag (Uptravi)”, 1 entry
  • “Selexipag Film Coated Tablets (T1)”, 1 entry
  • “Selexipag Film Coated Tablets (T2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.